MAHE inaugurates Harish & Bina Shah (HBSF) Clinical Block at Manipal Hospice and Respite Centre

IMT News Desk
IMT News Desk
· 4 min read

Shah, an esteemed alumnus of Manipal Institute of Technology (MIT Manipal, Batch 1975-80), has been an active supporter of MAHE’s initiatives in healthcare and education

The Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University, inaugurated the ‘Harish & Bina Shah Foundation (HBSF) Clinical Block’ at the Manipal Hospice and Respite Centre (MHRC), Manipal. This initiative is very significant, where an alumnus of MAHE has collaborated with his alma mater in its continued commitment to advancing healthcare infrastructure and compassionate patient care.

The ceremony was graced by Harish Shah, Chairperson of the Harish & Bina Shah Foundation as the Chief Guest. Shah, an esteemed alumnus of Manipal Institute of Technology (MIT Manipal, Batch 1975-80), has been an active supporter of MAHE’s initiatives in healthcare and education. Vasanti R Pai, Trustee, MAHE Trust, was also present during the event.

Harish Shah said, “I am indebted to MAHE for providing a values-based education journey, one which has shaped my life in significant ways. This new clinical block for palliative care amplifies our shared belief that every individual deserves dignity, comfort and respect, at all stages of life. It is an honour to support a cause which adds “life to days”.

Additionally, under the Harish & Bina Shah Foundation-MAHE Edu Empower Scholarship, in the current year, 19 students have been awarded a full scholarship for pursuing their engineering program at MIT, Manipal, and Bengaluru. The foundation is also an active supporter of the Access Life Assistance Foundation, an initiative which provides accommodation and allied services for children undergoing bone marrow transplantation and ensures that their families are also well supported. HBSF supports multiple centres, including one in Manipal.

Delivering Presidential address Dr HS Ballal, Pro Chancellor, MAHE, highlighted, “The naming of this Clinical Block represents far more than the creation of a physical infrastructure. The involvement of our alumni in this Endeavor reinforces the core value of our Founder, Dr TMA PAI, that the purpose of education is to empower and equip students to do good for society. We are deeply grateful to the Harish & Bina Shah Foundation for their vision and generosity in supporting this vital facility that will serve countless patients and families.”

In his special address Lt Gen (Dr) MD Venkatesh, VSM (Retd), Vice Chancellor, MAHE, “This day marks a major milestone in the history of any university when its Alumni come forward to support a societal cause, an amazing way to express gratitude. The facility inauguration today underscores MAHE’s dedication to advancing healthcare that truly transforms lives. MHRC will serve as a ray of hope and healing, combining clinical excellence with the warmth of human compassion that defines quality palliative care.”

Welcoming the gathering, Dr Sharath K Rao, Pro Vice Chancellor – Health Sciences, stated, “The integration of state-of-the-art facilities with our research initiatives at MHRC demonstrates the holistic approach to the healthcare ecosystem. This Clinical Block will provide our students and faculty with an exceptional environment to learn, practice, and innovate in the field of palliative and supportive care.” The event was followed by a special video presentation on MHRC.

This ceremony comes at a pivotal time as MHRC continues to expand its role in palliative care research and education. In October 2025, MAHE established the ICMR-MAHE Centre for Advanced Research (CAR) at MHRC, supported by a Rs. 12.84 crore grant from the Indian Council of Medical Research (ICMR).

Dr Seema Rajesh Rao, Director and Consultant, MHRC, provided an overview of the facilities at MHRC and delivered the Vote of Thanks.

Dr Anand Venugopal Chief Operating Officer, MAHE, Harinarayan Sharma, Chief Executive Officer, Manipal Foundation, Bengaluru and Dr Naveen Salins, Professor & Head, Department of Palliative Medicine and Supportive Care, KMC Manipal, were also present on the occasion.

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk